U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of Inspections and Investigations
  5. OII Inspectorates
  6. Office of Bioresearch Monitoring Inspectorate (OBMI)
  7. Chrissy J. Cochran, PhD, Director, Office of Bioresearch Monitoring Inspectorate (OBMI)
  1. Office of Bioresearch Monitoring Inspectorate (OBMI)

Chrissy J. Cochran, PhD, Director, Office of Bioresearch Monitoring Inspectorate (OBMI)

Blue Bar

 Chrissy J. Cochran

Chrissy J. Cochran is director of the Office of Bioresearch Monitoring Inspectorate (OBMI) within the Office of Inspections and Investigations (OII) in the Food and Drug Administration (FDA). She is responsible for working with each of FDA’s product centers to establish and manage the Bioresearch Monitoring Program (BIMO).

Dr. Cochran previously led the Division of Enforcement and Postmarketing Safety in the Office of Compliance in the Center for Drug Evaluation and Research. Prior to that she led the Good Laboratory Practice (GLP) compliance program in the Center for Devices and Radiological Health, monitored clinical trials at a large clinical research organization, and performed laboratory research at the Veteran’s Administration.

Dr. Cochran holds a Bachelor of Science in biochemistry from Worcester Polytechnic Institute, a Master of Science in Toxicology from Northeastern University, and a Doctor of Philosophy in Toxicology from University of Maryland, Baltimore. She completed her post-doctoral training at Johns Hopkins School of Public Health.  

 

 

Back to Top